Online inquiry

IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4378MR)

This product GTTS-WQ4378MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD80&CD86 gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005191.4; NM_001206924.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 941; 942
UniProt ID A0N0P2; P42081
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ4378MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5361MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ13586MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA QAX-576
GTTS-WQ3297MR IVTScrip™ mRNA-Anti-alpha toxin&<br />lukE, ASN-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-1
GTTS-WQ12380MR IVTScrip™ mRNA-Anti-SAA1, NEOD-001(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA NEOD-001
GTTS-WQ4055MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BI 655130
GTTS-WQ5020MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c4G7-N
GTTS-WQ4627MR IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BMS-986016
GTTS-WQ4061MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI 655130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW